MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDXG
CUSIPN/A
Phone770-651-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.25
Quick Ratio2.95
Price-To-Earnings
Trailing P/E Ratio28.48
Forward P/E Ratio13.20
P/E Growth0.78
Sales & Book Value
Annual Sales$245.01 million
Price / Sales2.63
Cash Flow$0.1766 per share
Price / Cash32.90
Book Value$1.21 per share
Price / Book4.80
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$11.97 million
Net Margins11.64%
Return on Equity17.49%
Return on Assets12.69%
Miscellaneous
Employees690
Outstanding Shares111,040,000
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group declared that its board has authorized a share buyback plan on Wednesday, December 13th 2017, which authorizes the company to repurchase $10,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) released its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The medical equipment provider had revenue of $84.60 million for the quarter, compared to the consensus estimate of $84.60 million. MiMedx Group had a return on equity of 17.49% and a net margin of 11.64%. The business's quarterly revenue was up 31.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.06 earnings per share. View MiMedx Group's Earnings History.
What price target have analysts set for MDXG?
4 brokers have issued 1 year price objectives for MiMedx Group's shares. Their predictions range from $9.00 to $21.00. On average, they expect MiMedx Group's share price to reach $16.00 in the next twelve months. View Analyst Ratings for MiMedx Group.
What are Wall Street analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "This morning (3/15/18), MDXG issued a press release announcing: 1) management expects 1Q18 revenue to exceed the high end of their guidance range and reiterates their 2018 guidance and 2) the U.S. Department of Justice (DOJ) is reviewing the SEC investigation matters. While MDXG’s business appears to be performing well despite the controversy swirling around the company, we believe investors may continue to heavily discount the fundamentals until more is known about the outcome of the Audit Committee’s investigation, the SEC investigation, and the DOJ review." (3/15/2018)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a increase in short interest in May. As of May 31st, there was short interest totalling 49,958,769 shares, an increase of 0.0% from the May 15th total of 49,955,512 shares. Based on an average trading volume of 2,793,322 shares, the short-interest ratio is presently 17.9 days. Approximately 48.7% of the company's shares are short sold. View MiMedx Group's Current Options Chain.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include Merit Medical Systems (MMSI), Nevro (NVRO), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Tandem Diabetes Care (TNDM), Orthofix International (OFIX), Atrion (ATRI), Intersect ENT (XENT), Cardiovascular Systems (CSII), OraSure Technologies (OSUR), Cryolife (CRY), AtriCure (ATRC) and K2M Group (KTWO).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Mr. Parker H. Petit, Chairman and Chief Exec. Officer (Age 79)
- Mr. William Charles Taylor, Pres, Chief Operating Officer and Director (Age 50)
- Mr. Michael J. Senken, CFO, Principal Accounting Officer & VP (Age 60)
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
Has MiMedx Group been receiving favorable news coverage?
News stories about MDXG stock have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MiMedx Group earned a news impact score of 0.08 on Accern's scale. They also assigned news headlines about the medical equipment provider an impact score of 45.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are MiMedx Group's major shareholders?
MiMedx Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.10%), STATE STREET CORP (10.01%), Millennium Management LLC (1.33%), Atlantic Trust Group LLC (1.33%), The Manufacturers Life Insurance Company (1.32%) and Northern Trust Corp (1.20%). View Institutional Ownership Trends for MiMedx Group.
Which institutional investors are selling MiMedx Group stock?
MDXG stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, American Century Companies Inc., Stephens Investment Management Group LLC, Prudential Financial Inc., Robeco Institutional Asset Management B.V., BlackRock Inc., Thrivent Financial for Lutherans and Guggenheim Capital LLC. View Insider Buying and Selling for MiMedx Group.
Which institutional investors are buying MiMedx Group stock?
MDXG stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Royal Bank of Canada, Thompson Investment Management Inc., Hussman Strategic Advisors Inc., Senzar Asset Management LLC, A.R.T. Advisors LLC, Pacific Ridge Capital Partners LLC and GSA Capital Partners LLP. View Insider Buying and Selling for MiMedx Group.
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $5.81.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $663.99 million and generates $245.01 million in revenue each year. MiMedx Group employs 690 workers across the globe.
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
